RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación
Artículo científico (JournalArticle)
Folate- and aCD47-functionalized lipid nanoparticles efficiently deliver mRNA and remodel pancreatic tumor microenvironment
[EN] Abstract: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive and treatment-resistant malignancies, with limited efficacy to conventional treatments such as surgical resection or chemotherapy. This clinical scenario underscores the need for novel therapeutic strategies. The development of multifunctional platforms capable of targeting tumors through multiple mechanisms offers an innovative strategy to overcome this challenge. Lipid nanoparticles (LNPs) offer a versatile platform capable of efficiently delivering genetic material. Moreover, through surface functionalization it is feasible to improve LNP performance optimizing therapeutic outcomes in a single formulation. Here, we explored a dual functionalization strategy of the LNP for tumor targeting and tumor remodeling to improve treatment efficacy. LNPs were designed for delivering reporter DNA plasmid or mRNA into the PDAC cellular models Capan-2 and PANC-1. The DNA plasmid contains a pancreatic cancer-specific chimeric promoter for transcriptional specificity to PDAC cells. Besides, LNPs were functionalized with folate and an anti-CD47 antibody to both target the folate receptor in PDAC cells and block CD47-mediated immune evasion. Both pDNA and mRNA LNPs targeted PDAC cells in a dose-dependent manner, with mRNA-LNPs demonstrating more efficient transfection. Notably, LNPs functionalized with the anti-CD47 antibody increased phagocytosis in vitro, and promoted an inflammatory phenotype of M1-like macrophages in mouse Capan-2 xenografts. This combinatorial design of the formulated LNP represents an innovative therapeutic strategy and opens future perspectives in the search for effective treatments for PDAC.
Keywords: Lipid nanoparticles; Immunotherapy; ACD47; Folate; Macrophages; Pancreatic cancer, This research was supported by European Union s Horizon 2020
research and innovation programme under grant agreement No 899708
(ULISES). The work has also received funding from projects PID2020-
119692RB-C22, PID2023-146637OB-C22, PID2021-128141OBC22,
PID2021-126304OB-C41 and PID2024-155683OB-C41 funded by
MCIN-Ministerio de Ciencia e Innovacion ¿ and by the European Regional
Development Fund A way of doing Europe. This study was also supported by the ERC Advanced Grant Edison (101052997), the Generalitat
Valenciana (CIPROM/2021/007) and CIBER (CB06/01/2012) and (RD21/0017/0012) Instituto de Salud Carlos III, the Generalitat de
Catalunya (SGR21/01169). The research leading to these results has also
received funding from la Caixa Foundation under agreement LCF/PR/
SP23/52950009. The Views and opinions expressed are however those
of the author(s) only and do not necessarily reflect those of the European
Union or European Research Council. Neither the European Union nor
the granting authority can be held responsible for them. J.M-L. is
grateful to the Spanish MECD for his FPU grant (FPU19/06219). PM.S-T.
is grateful to the Generalitat Valenciana for a postdoctoral Investigo
contract (INVEST/2023/443). We also acknowledge the support of
CERCA Programme/Generalitat de Catalunya.
Proyecto:
Agencia Estatal de Investigación / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2020-119692RB-C22
,
Agencia Estatal de Investigación / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2021-126304OB-C41
,
Agencia Estatal de Investigación / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2021-128141OB-C22
,
Agencia Estatal de Investigación / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2023-146637OB-C22
,
European Commission / H2020 899708
,
European Commission / HE 101052997
,
Generalitat Valenciana CIPROM/2021/007
,
Agencia Estatal de Investigación PID2024-155683OB-C41
,
Generalitat de Catalunya SGR21/01169
,
Instituto de Salud Carlos III CB06/01/2012
,
Instituto de Salud Carlos III RD21/0017/0012
,
Fundació Bancària Caixa d'Estalvis i Pensions de Barcelona LCF/PR/SP23/52950009
,
Ministerio de Educación y Cultura FPU19/06219
,
Generalitat Valenciana INVEST/2023/443